Skip to contentClarengateINTELLIGENCE
Coverage & freshness About Clarengate
Companies/10028228

Omass Therapeutics Limited

Research and experimental development on biotechnology · Oxford

ActiveUnited KingdomIncorporated 2016Private Limited Company
Register Ask analyst

Documents & history

Available account evidence and business events. This is not a complete filing history or document library.

Accounts to 2020-12-31

IXBRL · 277 source facts · 38 selected values

Not assessed
legacy record
Reporting period
2020-01-01 to 2020-12-31
Extraction status
Legacy / not assessed
Numeric facts
221
Documents processed
Not recorded
XBRL standards validation
Not assessed
Filing-profile validation
Not assessed
Parser
Legacy parser
Taxonomy
FRS-102-2019-01-01.xsd
Currency
GBP
Source identifier
Prod224_0090_10028228_20201231
Source archive
Accounts_Monthly_Data-May2021.zip

Registered details

10028228
Status
Active
Type
Private Limited Company
Incorporated
2016-02-26
Jurisdiction
—
Registered office
BUILDING 4000, JOHN SMITH DRIVE, OXFORD, OX4 2GX, ENGLAND

Classification

1 SIC codes
72110

Capital & company events

Reconstructed equity rounds and matched research funding.

Equity fundraising

4 SH01-derived rounds
2025-10-28
£88,299 raised
£26,948,259 estimated post-money
2024-07-31
£34,200,000 raised
£153,588,255 estimated post-money
Venture
2023-04-18
£6,000,000 raised
£119,387,049 estimated post-money
Venture
2022-03-16
£53,299,991 raised
£106,080,956 estimated post-money
Venture

Research and innovation

8 matched grants
High resolution cyclic ion mobility HDX mass spectrometry of protein dynamics and function
MRC · Research and Innovation - Infrastructure · 2023-03-01 – 2023-03-30 · with 2 other participants
£590,770
whole project
University Of ManchesterleadMicromass UK Ltd (Waters Corporation)OMass Therapeutics Ltd.
Integrating HDX-MS and Molecular Dynamics to investigate the mechanism of activation of the RORy by multiple small molecule modulatorsActive
EPSRC · Studentship · 2022-09-30 – 2026-09-29 · with 1 other participant
£0
whole project
University Of OxfordleadOMass Therapeutics Ltd.
Screening for anti-cancer agents against the smoothened receptor using novel mass spectrometry-based methodologyActive
BBSRC · Studentship · 2022-09-30 – 2026-09-29 · with 1 other participant
£0
whole project
University Of NottinghamleadOMass Therapeutics Ltd.
Mapping membrane protein dynamics in time and space with mass spectrometryActive
EPSRC · Fellowship · 2022-05-31 – 2027-05-30 · with 5 other participants
£1,018,512
whole project
University Of ManchesterleadMicromass UK Ltd (Waters Corporation)OMass TechnologiesOMass Therapeutics Ltd.University of BristolWaters Corporation
Molecular characterisation of MC2R/MRAP antagonists for the treatment of ACTH excess in pituitary and neuroendocrine tumours.
MRC · Studentship · 2020-09-30 – 2024-03-31 · with 1 other participant
£0
whole project
Queen Mary University Of LondonleadOMass Therapeutics Ltd.
Developing the hydrogen-deuterium exchange mass spectometry technology to interrogate membrane protein dynamics
EPSRC · Studentship · 2019-09-30 – 2023-12-31 · with 1 other participant
£0
whole project
King'S College LondonleadOMass Therapeutics Ltd.
Mapping G Protein Coupled Receptor Interactions using Carbene Footprinting
BBSRC · Studentship · 2019-09-30 – 2023-08-30 · with 1 other participant
£0
whole project
University Of NottinghamleadOMass Therapeutics Ltd.
A new platform for drug discovery for membrane protein targetsLead
Innovate UK · Collaborative R&D · 2018-03-01 – 2021-05-31 · with 1 other participant
£461,624
awarded
Omass Technologies Limitedlead£461,624
University of Oxford£20,098